- Previous Close
0.1050 - Open
0.1050 - Bid 0.1050 x --
- Ask 0.1150 x --
- Day's Range
0.1050 - 0.1100 - 52 Week Range
0.1000 - 0.6000 - Volume
186 - Avg. Volume
102,744 - Market Cap (intraday)
8.135M - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1100 - Earnings Date Feb 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, and solid cancers, such as lung, ovarian, anogenital, and glioblastoma multiforme cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
www.inviongroup.com--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: IVX.AX
View MorePerformance Overview: IVX.AX
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IVX.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IVX.AX
View MoreValuation Measures
Market Cap
8.14M
Enterprise Value
7.40M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.62
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.39%
Return on Equity (ttm)
-43.80%
Revenue (ttm)
1.47M
Net Income Avi to Common (ttm)
-6.79M
Diluted EPS (ttm)
-0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
736.45k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-619.08k